GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

INR 2656.45

(-0.16%)

Operating Income Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual operating income in 2023 was 13.6 Billion INR , up 0.78% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly operating income in 2024 Q2 was 3.04 Billion INR , up 42.37% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported an annual operating income of 8.39 Billion INR in 2022, up 9.11% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported an annual operating income of 7.69 Billion INR in 2021, up 1.01% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating income of 3.04 Billion INR for 2024 Q2, up 42.37% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating income of 2.29 Billion INR for 2023 Q3, down -23.54% from previous quarter.

Annual Operating Income Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Operating Income of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Operating Income	Operating Income Growth
2023	13.6 Billion INR	0.78%
2022	8.39 Billion INR	9.11%
2021	7.69 Billion INR	1.01%
2020	7.61 Billion INR	40.2%
2019	5.43 Billion INR	-16.83%
2018	6.53 Billion INR	24.45%
2017	5.24 Billion INR	33.66%
2016	3.92 Billion INR	-15.39%
2015	4.64 Billion INR	-5.01%
2014	4.88 Billion INR	-5.98%
2013	5.19 Billion INR	-35.0%
2012	7.99 Billion INR	-13.79%
2011	9.27 Billion INR	6.39%
2010	8.71 Billion INR	14.51%
2009	7.61 Billion INR	8.58%
2008	7.01 Billion INR	11.71%
2007	6.27 Billion INR	10.8%
2006	5.66 Billion INR	15.95%
2005	4.88 Billion INR	14.15%
2004	4.27 Billion INR	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	2.14 Billion INR	-10.47%
2024 Q2	3.04 Billion INR	42.37%
2023 Q3	2.29 Billion INR	-23.54%
2023 FY	8.45 Billion INR	0.78%
2023 Q4	2.39 Billion INR	4.41%
2023 Q1	1.63 Billion INR	-9.02%
2023 Q2	2.99 Billion INR	82.72%
2022 FY	8.39 Billion INR	9.11%
2022 Q2	2.62 Billion INR	63.36%
2022 Q1	1.6 Billion INR	-9.87%
2022 Q3	2.35 Billion INR	-10.22%
2022 Q4	1.8 Billion INR	-23.54%
2021 Q4	1.78 Billion INR	-6.28%
2021 Q1	1.33 Billion INR	-28.7%
2021 FY	7.69 Billion INR	1.01%
2021 Q2	2.58 Billion INR	93.28%
2021 Q3	1.9 Billion INR	-26.52%
2020 Q1	923 Million INR	65.64%
2020 FY	7.61 Billion INR	40.2%
2020 Q4	1.87 Billion INR	-4.49%
2020 Q3	1.96 Billion INR	7.56%
2020 Q2	1.82 Billion INR	98.16%
2019 Q3	1.06 Billion INR	-38.09%
2019 FY	5.43 Billion INR	-16.83%
2019 Q4	557.24 Million INR	-47.46%
2019 Q1	1.46 Billion INR	-4.85%
2019 Q2	1.71 Billion INR	17.15%
2018 Q2	1.53 Billion INR	19.0%
2018 FY	6.53 Billion INR	24.45%
2018 Q4	1.53 Billion INR	22.84%
2018 Q3	1.25 Billion INR	-18.51%
2018 Q1	1.29 Billion INR	0.0%
2017 FY	5.24 Billion INR	33.66%
2017 Q1	121.6 Million INR	0.0%
2016 FY	3.92 Billion INR	-15.39%
2015 FY	4.64 Billion INR	-5.01%
2014 FY	4.88 Billion INR	-5.98%
2013 FY	5.19 Billion INR	-35.0%
2012 FY	7.99 Billion INR	-13.79%
2011 FY	9.27 Billion INR	6.39%
2010 FY	8.71 Billion INR	14.51%
2009 FY	7.61 Billion INR	8.58%
2008 FY	7.01 Billion INR	11.71%
2007 FY	6.27 Billion INR	10.8%
2006 FY	5.66 Billion INR	15.95%
2005 FY	4.88 Billion INR	14.15%
2004 FY	4.27 Billion INR	0.0%

Peer Operating Income Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Operating Income	Operating Income Difference
Abbott India Limited	13.79 Billion INR	1.392%
Cipla Limited	105.7 Billion INR	87.133%
Gland Pharma Limited	16.45 Billion INR	17.322%
Kopran Limited	675.44 Million INR	-1913.781%
Marksans Pharma Limited	7.79 Billion INR	-74.573%
NGL Fine-Chem Limited	416.27 Million INR	-3167.589%
Pfizer Limited	9.61 Billion INR	-41.515%
Sanofi India Limited	12.19 Billion INR	-11.556%
SMS Pharmaceuticals Limited	1.34 Billion INR	-914.967%
TTK Healthcare Limited	249.89 Million INR	-5343.205%